New Insights on Piclidenoson for Canine Osteoarthritis
Can-Fite BioPharma Ltd. (NYSE American: CANF) has made significant strides in advancing veterinary medicine, particularly with their innovative treatment for canine osteoarthritis—Piclidenoson. This promising drug candidate is currently undergoing advanced clinical studies spearheaded by their veterinary partner, Vetbiolix.
The Role of Vetbiolix in Clinical Studies
Recently, Vetbiolix successfully completed preliminary clinical trials demonstrating Piclidenoson's effectiveness in alleviating symptoms of osteoarthritis in dogs. This groundbreaking research showcases the potential of Piclidenoson in the veterinary field, which is seen as a significant opportunity. The veterinary market for pet medications continues to expand, showcasing the need for effective treatments in companion animals suffering from chronic conditions such as osteoarthritis.
The Market Opportunity
The arthritis treatment market for pets is projected to be valued at approximately $3.8 billion in the near future, with growth trends suggesting it could reach around $6.3 billion by the end of the decade. Can-Fite and Vetbiolix anticipate that Piclidenoson could capture up to 6% of this lucrative market, potentially translating to peak sales of around $445 million worldwide by 2034. The financial outlook for Can-Fite, comprising a 15% royalty on these sales, presents an opportunity for significant revenue, potentially reaching up to $325 million over the next ten years, assuming successful regulatory approval.
Comparison to Existing Treatments
Currently, treatment options for canine osteoarthritis are limited to oral non-steroidal anti-inflammatory drugs (NSAIDs) that primarily manage symptoms while posing significant side effects. There are also injectable disease-modifying osteoarthritis drugs (DMOADs) that aim to slow disease progression. Piclidenoson stands out as a potential game-changer—its oral administration combined with a favorable safety profile in human and animal studies suggests it could provide a more effective and safer alternative for dogs.
Statements from Can-Fite Leadership
Highlighting these advances, Dr. Sari Fishman, VP of Business Development at Can-Fite, remarked on the extraordinary opportunity the veterinary market presents. She noted, "The combination of a sizable market and quicker approval timelines for veterinary products could lead to tangible revenues for Can-Fite. With Piclidenoson’s proven safety and efficacy, we believe it can significantly benefit the increasing population of dogs suffering from osteoarthritis."
Vetbiolix's Commitment to Veterinary Medicine
Matthieu Roquette, President of Vetbiolix, expressed enthusiasm for the ongoing research, stating, "The high standard of preclinical and clinical data from our studies indicates that Piclidenoson is uniquely positioned to address the critical unmet needs in veterinary medicine for managing osteoarthritis in both dogs and cats." This innovative approach demonstrates Vetbiolix's commitment to transforming breakthroughs in human medicine into effective products for pets.
Intellectual Property and Future Developments
Building on the existing patent for Piclidenoson in the U.S., Vetbiolix is pursuing additional patent applications derived from the new dog clinical study results. This step not only solidifies their position within the veterinary sector but also emphasizes the ongoing commitment to developing novel therapies that meet the needs of pets and their owners.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) is a clinical-stage drug development company focused on creating advanced therapies for inflammatory diseases and cancers in both human and veterinary medicine. Their lead drug candidate, Piclidenoson, has recently shown promise in a Phase III trial for psoriasis, and they are embarking on additional trials for various indications, including hepatocellular carcinoma. Their existing products also hold the potential to treat other cancers, underscoring Can-Fite's commitment to innovative healthcare solutions.
Frequently Asked Questions
What is Piclidenoson and its intended use?
Piclidenoson is an orally administered medication being developed by Can-Fite to treat canine osteoarthritis and is based on a proven safety profile in previous studies.
How large is the market for canine osteoarthritis treatments?
The market is valued at approximately $3.8 billion and is expected to grow significantly, reaching around $6.3 billion by the end of the decade.
What are the expected sales for Piclidenoson?
Can-Fite estimates that Piclidenoson could capture up to 6% of the canine osteoarthritis treatment market, potentially leading to peak sales of about $445 million by 2034.
What makes Piclidenoson superior to current treatments?
Piclidenoson offers a potential solution with a more favorable safety profile compared to existing NSAIDs and DMOADs, reducing harmful side effects while effectively managing osteoarthritis symptoms.
Who is Vetbiolix, and what is their role?
Vetbiolix is a veterinary partner of Can-Fite focusing on developing innovative treatments for pets. They are conducting advanced clinical studies for Piclidenoson to address the unmet medical needs in veterinary care.
